Donor-Derived Strains Predict FMT Response for Ulcerative Colitis Donor-Derived Strains Predict FMT Response for Ulcerative Colitis

Core strains from human donors limited ulcerative colitis in mouse models, which may shape strategies for more effective microbial therapy.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Related Links:

ConclusionsThe risk of perioperative thrombosis in UC patients was considered similar to that in CRC, so active thromboprophylaxis should be administered to UC patients while paying attention to bleeding.Trial registrationThis study was registered with the Japanese Clinical Trials Registry as UMIN000042004 (http://www.umin.ac.jp/ctr/index.htm).
Source: Surgery Today - Category: Surgery Source Type: research
Conditions:   Ulcerative Colitis;   Efficacy, Self;   Biologics;   Mesalazine Interventions:   Drug: Infliximab;   Drug: Vedolizumab;   Drug: Mesalazine Sponsor:   Sixth Affiliated Hospital, Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: The Norwegian version of MFI-20 is valid, reliable and responsive. The instrument can safely be used in studies using fatigue as an endpoint.PMID:35076321 | DOI:10.1080/00365521.2022.2029939
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Authors: Source Type: research
Aging Clin Exp Res. 2022 Jan 25. doi: 10.1007/s40520-022-02076-1. Online ahead of print.ABSTRACTThe prognostic impact of inflammatory bowel disease (IBD), chronic inflammatory conditions consisting of ulcerative colitis (UC), and Crohn's disease (CD) on the risk of dementia has been poorly investigated. We evaluated the risk of dementia in IBD patients by a systematic review and meta-analysis of the available data. Three studies, enrolling 121.827 patients [14.839 IBD (12.1%) and 106.961 (87.7%) controls, respectively] were included in the analysis. Of these, 57.7% (n = 8.571) had UC, while 42.2% (n = 6268) had CD. The mea...
Source: Aging Clinical and Experimental Research - Category: Geriatrics Authors: Source Type: research
Eur J Pharm Biopharm. 2022 Jan 21:S0939-6411(22)00013-3. doi: 10.1016/j.ejpb.2022.01.007. Online ahead of print.ABSTRACTThe ability of mesenchymal stromal cells (MSCs) to release a plethora of immunomodulatory factors makes them valuable candidates to overcome inflammatory bowel diseases (IBD). However, this cell therapy approach is still limited by major issues derived from nude MSC-administration, including a rapid loss of their immunomodulatory phenotype that impairs factor secretion, low persistence and impossibility to retrieve the cells in case of adverse effects. Here, we designed a licensing hydrogel system to addr...
Source: European Journal of Pharmaceutics and Biopharmaceutics - Category: Drugs & Pharmacology Authors: Source Type: research
Journal of Agricultural and Food ChemistryDOI: 10.1021/acs.jafc.1c07316
Source: Journal of Agricultural and Food Chemistry - Category: Food Science Authors: Source Type: research
Condition:   Pediatric Ulcerative Colitis in Remission Interventions:   Drug: Fecal Microbiota Transplantation by Stool capsules;   Drug: Fecal Microbiota Transplantation by Intra-rectal enemas Sponsors:   Assistance Publique - Hôpitaux de Paris;   MRSU 938 - Research Center of Saint Antoine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
World J Gastroenterol. 2021 Dec 21;27(47):8047-8057. doi: 10.3748/wjg.v27.i47.8047.ABSTRACTInflammatory bowel disease (IBD) is a chronic condition that requires continuous medical treatment. To date, the medical management of patients with moderately-to-severely active IBD who develop dependence or resistance to corticosteroids is based on immunomodulator drugs. Such therapies are licenced after passing through three phases of randomized controlled trials (RCTs), and are subsequently adopted in clinical practice. However, the real-life population of IBD patients who require these therapies can significantly differ from tho...
Source: World Journal of Gastroenterology - Category: Gastroenterology Authors: Source Type: research
CONCLUSIONS: In this large study among older adults (≥66 years of age), IBD was positively associated with gastrointestinal cancers. Associations with extraintestinal cancers may reflect the effect of immunosuppressive medications.PMID:35071980 | PMC:PMC8767622 | DOI:10.1093/jncics/pkab096
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
World J Gastroenterol. 2021 Dec 28;27(48):8242-8261. doi: 10.3748/wjg.v27.i48.8242.ABSTRACTInflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways invol...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Source Type: research
More News: Gastroenterology | Inflammatory Bowel Disease | Ulcerative Colitis